Skip to main content
Overview of the Current Development Landscape in Chronic Lymphocytic Leukemia, Part 3
Austin J. Combest, PharmD, BCOP, MBA, Ryan C. Danford, PharmD, Elizabeth R. Andrews, PharmD, Ashley Simmons, PharmD, Paulina McAtee, PharmD, Dirk J. Reitsma, MD
Read More
Original Research
Efficacy and Cost Analysis of a Plerixafor Protocol for Peripheral Blood Stem-Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma
Victoria H. Wehr, PharmD, Jill M. Comeau, PharmD, BCOP
Read More
Making an Informed Treatment Choice for Aggressive Non-Hodgkin Lymphoma: The R-CHOP Regimen versus EPOCH-R
Marjorie Adams Curry, PharmD, BCOP, Susanne Liewer, PharmD, BCOP
Read More
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy
Read More
HOPA Conference Highlights
Meg Barbor, MPH
Read More
FDA Updates
Daratumumab Combination Approved for Multiple Myeloma
Read More
Online First
Challenges in ALK-Positive NSCLC Management
Meg Barbor, MPH
Read More
Online First
Lowering the High Cost of USP 800 Compliance
Meg Barbor, MPH
Read More
Online First
Navigating the New Requirements for USP 800 Drugs
Read More
Online First
FDA Updates
Sustol, First Extended-Release 5-HT3 Approved for the Prevention of CINV
Read More
Page 167 of 196
Results 1661 - 1670 of 1955